UNSPSC 51422338: Dexamethasone metasulfobenzoate sodium

This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C22H29FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7S5I7G3JQL, chemically known as 9-fluoro-11.beta.,17, 21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione but more generally known as dexamethasone, which bears US NIH Compound Identifier 3003. European Medicines Agency schedules Dexamethasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07017MIG.

UNSPSC 51422338 Dexamethasone metasulfobenzoate sodium is a Commodity code that, based on recent state and local solicitation activity, covers pharmaceutical products and related health-system procurement rather than the specific corticosteroid compound its name suggests. State and local health authorities and health and human services agencies are using this code to solicit naloxone products, safe drug deactivation systems, and direct-to-manufacturer prescription programs that support community health initiatives and pharmacy benefit management. The issuing bodies include county health departments and state health and human services commissions operating their own pharmaceutical procurement programs.

Seminole County, Florida posted an IFB on June 30, 2026 (Solicitation IFB60459723LAS, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with a one-year renewal option and is potentially FEMA-funded. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, seeking information on vendors' experience with direct contracting for self-insured employers and state agencies outside traditional pharmacy benefit manager and group purchasing organization channels. Recent activity is concentrated in Florida and Texas; the code shows limited but concrete health-system procurement momentum.